| pubmed-article:9053498 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9053498 | lifeskim:mentions | umls-concept:C0035569 | lld:lifeskim |
| pubmed-article:9053498 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
| pubmed-article:9053498 | lifeskim:mentions | umls-concept:C0796507 | lld:lifeskim |
| pubmed-article:9053498 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:9053498 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9053498 | pubmed:dateCreated | 1997-3-10 | lld:pubmed |
| pubmed-article:9053498 | pubmed:abstractText | Immunotoxins could improve outcome in small-cell lung cancer (SCLC) by targeting tumor cells that are resistant to chemotherapy and radiation. N901 is a murine monoclonal antibody that binds to the CD56 (neural cell adhesion molecule [NCAM]) antigen found on cells of neuroendocrine origin, including SCLC. N901-bR is an immunoconjugate of N901 antibody with blocked ricin (bR) as the cytotoxic effector moiety. N901-bR has more than 700-fold greater selectivity in vitro for killing the CD56+ SCLC cell line SW-2 than for an antigen-negative lymphoma cell line. Preclinical studies suggested the potential for clinically significant cardiac and neurologic toxicity. We present a phase I study of N901-bR in relapsed SCLC. | lld:pubmed |
| pubmed-article:9053498 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9053498 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9053498 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9053498 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9053498 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9053498 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9053498 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9053498 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9053498 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9053498 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9053498 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:EliasAA | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:CookSS | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:RitzJJ | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:LambertJ MJM | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:SkarinAA | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:EsseltineDD | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:LynchT JTJJr | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:CoralFF | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:BlattlerW AWA | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:CollinsonA... | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:WenPP | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:ArinielloP... | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:ShefnerJJ | lld:pubmed |
| pubmed-article:9053498 | pubmed:author | pubmed-author:BramanGG | lld:pubmed |
| pubmed-article:9053498 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9053498 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:9053498 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9053498 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9053498 | pubmed:pagination | 723-34 | lld:pubmed |
| pubmed-article:9053498 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:meshHeading | pubmed-meshheading:9053498-... | lld:pubmed |
| pubmed-article:9053498 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9053498 | pubmed:articleTitle | Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. | lld:pubmed |
| pubmed-article:9053498 | pubmed:affiliation | Hematology-Oncology Unit, Massachusetts General Hospital, Boston 02114, USA. Lynch.Thomas@mgh.harvard.edu | lld:pubmed |
| pubmed-article:9053498 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9053498 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9053498 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9053498 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9053498 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9053498 | lld:pubmed |
